Table 3.
Multivariable analysis of the 28-gene signature in predicting metastatic outcome.
| Study | Variable | Multivariable analysis | |
|---|---|---|---|
| Pooled cohort | Hypoxia | 2.57 (1.38–4.77) | 0.003 |
| Decipher | 1.22 (1.06–1.41) | 0.007 | |
| Gleason Group 2 VS 1 | 1.13 (0.14–9.30) | 0.907 | |
| Gleason Group 3 VS 1 | 3.50 (0.43–28.26) | 0.239 | |
| Gleason Group 4 VS 1 | 3.67 (0.45–30.06) | 0.226 | |
| Gleason Group 5 VS 1 | 5.83 (0.74–45.96) | 0.094 | |
| Log2 pre-treatment PSA | 1.02 (0.79–1.33) | 0.864 | |
| AGE | 0.99 (0.95–1.03) | 0.522 | |
| SVI | 2.01 (1.15–3.51) | 0.014 | |
| SM | 1.45 (0.84–2.51) | 0.18 | |
| ECE | 1.39 (0.70–2.75) | 0.346 | |
| LNI | 1.95 (1.04–3.67) | 0.037 | |
PSA: prostate specific antigen; SVI: seminal vesicle invasion; SM: surgical margin; ECE: extracapsular extension; LNI: lymph node invasion.